Marlow Hernandez - Dec 1, 2021 Form 4 Insider Report for Cano Health, Inc. (CANO)

Role: CEO and President, Director
Signature: /s/ David J. Armstrong, Attorney-in-Fact
Stock symbol: CANO
Transactions as of: Dec 1, 2021
Transactions value $: $187,637
Form type: 4
Date filed: 12/6/2021, 03:05 PM
Previous filing: Dec 1, 2021
Next filing: Dec 7, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CANO	Class A Common Stock	Purchase	$109K	+12.5K	+0.44%	$8.75^*	2.88M	Dec 3, 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CANO	Warrants to purchase Class A Common Stock	Purchase	$25.9K	+10K	+2.34%	$2.59^*	436K	Dec 1, 2021	Class A Common Stock	10K	$11.50	Direct
transaction	CANO	Warrants to purchase Class A Common Stock	Purchase	$52.4K	+22K	+5.04%	$2.38^*	458K	Dec 3, 2021	Class A Common Stock	22K	$11.50	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $2.20 to $2.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1)-(2) to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $2.20 to $2.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1)-(2) to this Form 4.